

**Streamlined chemoenzymatic total synthesis of prioritized ganglioside cancer antigens**

Journal:	<i>Organic & Biomolecular Chemistry</i>
Manuscript ID	OB-COM-05-2018-001087
Article Type:	Communication
Date Submitted by the Author:	09-May-2018
Complete List of Authors:	Yu, Hai; University of California, Department of Chemistry Santra, Abhishek; University of California-Davis, Department of Chemistry Li, Yanhong; University of California, Department of Chemistry McArthur, John; University of California, Davis, Department of Chemistry Ghosh, Tamashree; University of California-Davis, Department of Chemistry Yang, Xiaoxiao; University of California-Davis, Department of Chemistry Wang, Peng George; Georgia State University, Department of Chemistry Chen, Xi; University of California, Davis, Department of Chemistry

Streamlined chemoenzymatic total synthesis of prioritized ganglioside cancer antigens

Received 00th January 20xx,
Accepted 00th January 20xx

Hai Yu,^a Abhishek Santra,^a Yanhong Li,^a John B. McArthur,^a Tamashree Ghosh,^a Xiaoxiao Yang,^a
Peng G. Wang,^b and Xi Chen^{*a}

DOI: 10.1039/x0xx00000x

www.rsc.org/

A highly efficient streamlined chemoenzymatic strategy for total synthesis of four prioritized ganglioside cancer antigens GD2, GD3, fucosyl GM1, and GM3 from commercially available lactose and phytosphingosine is demonstrated. Lactosyl sphingosine (Lac β Sph) was chemically synthesized (in 13-gram scale), subjected to sequential one-pot multienzyme (OPME) glycosylation reactions with facile C18-cartridge purification, followed by an improved acylation condition to form target gangliosides, including fucosyl GM1 which has never been synthesized before.

Gangliosides are sialic acid-containing glycosphingolipids presented broadly in vertebrate cells but are particularly abundant in the nervous cells.^{1, 2} They are involved in lipid raft formation,³ viral and bacterial infection,^{4, 5} immune regulation,⁶ and axon outgrowth.² Exogenous GM1 has shown potential in treating central nervous system injuries and neurodegenerative diseases.^{7, 8} Aberrant expressing of some gangliosides is linked to cancer progression.⁹ In fact, among 75 cancer antigens prioritized in a 2009 National Cancer Institute pilot project report,¹⁰ four are gangliosides including GD2, GD3, fucosyl GM1, and GM3 (Fig. 1).

Due to their important functions, gangliosides are attractive but challenging synthetic targets.^{11, 12} For example, among four prioritized ganglioside cancer antigens, only GM3 has been synthesized chemically and chemoenzymatically,¹²⁻¹⁵ GD2¹⁶ and GD3¹⁷ have been synthesized by chemical methods only. Fucosyl GM1 has never been synthesized before and only its oligosaccharide portion has been chemically synthesized.^{18, 19} Chemical synthetic procedures for gangliosides encounter notable challenges including hard-to-control regio- and stereo-selectivities in sialylation, and low yields for glycosylating the

oligosaccharide with the lipid.¹¹ Chemoenzymatic synthesis of gangliosides has been reported only for GM3.^{12, 20, 21} Therefore, efficient synthetic approaches for diverse gangliosides are lacking but are urgently needed.




Fig. 1 Structures of prioritized ganglioside cancer antigens GM3 (1), fucosyl GM1 (2), GD3 (3), and GD2 (4).

Biosynthetically, gangliosides are formed in the Golgi from lactosylceramide (Lac β Cer) catalyzed by type II membrane protein glycosyltransferases.²² These processes are not readily duplicated in vitro as Lac β Cer is not soluble in water and the glycosyltransferases involved are immobilized on the Golgi membrane. Recently, we showed that α -Gal pentasaccharyl ceramide, a neutral glycosphingolipid, can be chemoenzymatically synthesized from water soluble lactosyl sphingosine (Lac β Sph) with simple C18-cartridge solid phase extraction (SPE) purification procedures followed by acylation.²³ Herein, we develop high-yield streamlined chemoenzymatic processes for total synthesis of synthetically challenging complex gangliosides. A 13-gram-scale synthetic procedure is established for producing Lac β Sph from commercially available inexpensive lactose and phytosphingosine. Sequential one-pot multienzyme (OPME) chemoenzymatic synthetic methods,

^a Department of Chemistry, University of California, One Shields Avenue, Davis, CA 95616, USA.

E-mail: xiichen@ucdavis.edu


^b Department of Chemistry and Center of Diagnostics & Therapeutics, Georgia State University, Atlanta, GA 30303, USA.

Electronic Supplementary Information (ESI) available: Experimental procedures, NMR and HRMS data, and NMR spectra of products. See DOI: 10.1039/x0xx00000x

combined with facile C18-cartridge purification scheme, are successfully developed for the production of negatively charged complex gangliosides from Lac β Sph in a highly efficient manner. An improved acylation procedure is identified to convert glycosylsphingosines to target gangliosides in excellent 98–99% yields. The four prioritized ganglioside cancer antigens including GM3 (**1**), fucosyl GM1 (**2**), GD3 (**3**), and GD2 (**4**) (Figure 1) are successfully obtained in high yields.

To obtain target gangliosides, Lac β Sph (**5**)²³ was prepared from lactose and phytosphingosine in a 13-gram scale to demonstrate the efficiency of the streamlined chemical synthetic procedure and to provide a sufficient amount of starting material for glycosphingolipid synthesis. The synthesis was achieved in 12 steps in an overall 40% yield (see ESI).


GM3 (**1**) is the simplest ganglioside and is a common precursor for more complex gangliosides. It is overexpressed by many types of tumors, including malignant melanoma, leukemia, pulmonary cancer, neuroectodermal tumor.^{24, 25} The corresponding GM3 sphingosine (GM3 β Sph, **6**) lacking the fatty acyl chain was readily obtained from Lac β Sph (**5**) and monosaccharide *N*-acetylneuraminic acid (Neu5Ac) using a one-pot two-enzyme sialylation system containing *Neisseria meningitidis* CMP-sialic acid synthetase (NmCSS)²⁶ and *Pasteurella multocida* α 2–3-sialyltransferase 3 (PmST3) that can use both oligosaccharides and glycolipids as acceptor substrates²⁷ (Scheme 1). PmST3²⁸ and its mutants^{29, 30} preferring oligosaccharides as acceptors are not suitable sialyltransferases for the reaction. A simple C18-cartridge SPE was used for purification by loading the sample to the C18-cartridge, washing the cartridge with water to completely remove excess Neu5Ac, cytidine 5'-monophosphate (CMP)-Neu5Ac, cytidine 5'-triphosphate (CTP), by-product CMP, and others, followed by eluting the cartridge with 60% acetonitrile (CH₃CN) in water to obtain pure GM3 β Sph (**6**) in a gram-scale (1.44 g) with an excellent 96% yield. The remaining Lac β Sph was recovered by eluting the cartridge with pure CH₃CN. The whole process took about 25 minutes in contrast to several hours using standard silica gel chromatography.



Scheme 1 Gram-scale (1.44 g) synthesis of GM3 β Sph (**6**) by one-pot multi-enzyme (OPME) sialylation of Lac β Sph (**5**).

Fucosyl GM1 (**2**) has been found to be absent from normal tissues but be expressed on the cell surface of small-cell lung cancer (SCLC)³¹ which accounts for 10–15% of lung cancer cases and remains as one of the leading causes of death in the United

States.³² Fucosyl GM1 is therefore an excellent candidate for cancer vaccine development and for the development of antibodies for detecting SCLC. The corresponding fucosyl GM1 sphingosine (Fuc-GM1 β Sph, **9**) was obtained from GM3 β Sph (**6**) using three OPME reactions carried out in sequential (Scheme 2).



Scheme 2 Sequential one-pot multi-enzyme (OPME) synthesis of Fuc-GM1 β Sph (**9**) from GM3 β Sph (**6**).

A one-pot four-enzyme *N*-acetylgalactosamine (GalNAc)-activation and transfer system³³ containing recombinant *Bifidobacterium longum* strain ATCC55813 *N*-acetylhexosamine-1-kinase (BLNAhK),³⁴ *Pasteurella multocida* *N*-acetylglucosamine uridylyltransferase (PmGlmU),³⁵ *Pasteurella multocida* inorganic pyrophosphatase (PmPpA),³⁶ and *Campylobacter jejuni* β 1–4-*N*-acetylgalactosaminyltransferase (CjCgtA),³³ was used to glycosylate GM3 β Sph (**6**) to form GM2 β Sph (**7**). Although GM3 β Sph (**6**) was a less favored acceptor for CjCgtA compared to GM3 oligosaccharide,³³ adding a larger amount of CjCgtA was able to push the reaction to completion. GM2 β Sph (**7**, 120 mg, 98% yield) was readily purified by passing the reaction mixture through the C18 cartridge and eluting with 45% CH₃CN in water.

GM1 β Sph (**8**) was then synthesized from GM2 β Sph (**7**) using a one-pot four-enzyme galactose-activation and transfer system containing *Escherichia coli* galactokinase (EcGalK),³⁷ *Bifidobacterium longum* UDP-sugar pyrophosphorylase (BLUSP),³⁸ PmPpA, and *Campylobacter jejuni* β 1–3-galactosyltransferase (CjCgtB).³⁹ Again, GM2 β Sph (**7**) was a less efficient acceptor for CjCgtB compared to GM2 oligosaccharide,³³ but adding a larger amount of CjCgtB was able to complete the reaction without the complication of


adding more than one galactose residue observed previously for galactosylation of GM2 oligosaccharide by CjCgtB.³³ GM1 β Sph (**8**, 57 mg, 99% yield) was readily purified by passing the reaction mixture through the C18 cartridge and eluting with 40% CH₃CN in water.

To synthesize Fuc-GM1 β Sph (**9**) from GM1 β Sph (**8**), a suitable α 1–2-fucosyltransferase was needed. Despite its preference towards β 1–3-linked galactoside acceptors, *Thermosynechococcus elongates* α 1–2-fucosyltransferase (Te2FT)⁴⁰ could not fucosylate GM1 β Sph (**8**). *Escherichia coli* O126 α 1–2-fucosyltransferase (EcWbgL)⁴¹ that prefers β 1–4-linked galactoside acceptors but is also active towards β 1–3-linked galactosides was then cloned (see ESI) and found to be very efficient in using GM1 β Sph (**8**) as the acceptor. Fuc-GM1 β Sph (**9**, 55 mg) was synthesized in a quantitative yield from GM1 β Sph (**8**) using a one-pot three-enzyme fucose-activation and transfer system containing EcWbgL and guanosine 5'-diphosphate fucose (GDP-Fuc) biosynthetic enzymes including *Bacteroides fragilis* bifunctional L-fucokinase and guanidine 5'-diphosphate (GDP)-fucose pyrophosphorylase (BfFKP)⁴² and PmPpA (Scheme 2) followed by C18 cartridge-purification by eluting with 40% of CH₃CN in water. Remarkable, three OPME glycosylation reactions carried out in sequential led to the formation of complex Fuc-GM1 β Sph (**9**) from GM3 β Sph (**6**) in an excellent 97% overall yield. The overall process for the formation of Fuc-GM1 β Sph (**9**) from chemically synthesized Lac β Sph (**5**) involved four sequential OPME reaction with a total yield of 93%.

GD3 is a disialoganglioside overexpressed on melanomas, neuroectodermal tumors including neuroblastoma and glioma, as well as cancers of lung, breast, colon, prostate, and ovary.^{43, 44} Therefore, GD3 has received a considerable attention as a promising immunotherapeutic target for cancer therapy.^{9, 44, 45} The corresponding GD3 β Sph (**10**) was successfully synthesized from GM3 β Sph (**6**) and Neu5Ac using a one-pot two-enzyme sialylation reaction containing NmCSS and *Campylobacter jejuni* α 2–3/8-sialyltransferase (CjCstII)^{46, 47} (Scheme 3). As CjCstII could continue to add an additional α 2–8-linked Neu5Ac to GD3 β Sph (**10**), GT3 β Sph was produced as a minor product and was eluted from the C18-cartridge using 30% of CH₃CN in water. The GD3 β Sph (**10**, 910 mg, 62% yield) was then readily obtained by eluting the cartridge with 35% of CH₃CN in water.

GD2 is another disialoganglioside cancer antigen expressed predominantly in the CD44hiCD24lo breast cancer stem cells isolated from human breast cancer cells.⁴⁸ It has also been found in melanomas, gliomas, and neuroblastomas.⁴⁹ Therapeutic effects of anti-GD2 monoclonal antibodies against neuroblastomas have been reported.⁵⁰ GD2 (**12**) has the highest priority compared to the other three prioritized ganglioside cancer antigens GM3 (#48), fucosyl GM1 (#41), and GD3 (#40).¹⁰ Similar to the synthesis of GM2 β Sph (**7**) from GM3 β Sph (**6**), GD2 β Sph (**11**) was readily synthesized from GD3 β Sph (**10**) using the one-pot multienzyme GalNAc-activation and glycosylation system containing BLNahK, PmGlmU, PmPpA, and CjCgtA (Scheme 3). As GD3 β Sph (**10**) was not an efficient substrate for CjCgtA comparing to GD2 oligosaccharide,³³ a larger amount of CjCgtA was used to push

the reaction to completion. GD2 β Sph (**11**, 34 mg) was easily purified by passing the reaction mixture through C18 cartridge and eluting with 35% of CH₃CN in water with an excellent 98% yield.



Scheme 3 Sequential one-pot multienzyme (OPME) synthesis of GD3 β Sph (**10**) and GD2 β Sph (**11**) from GM3 β Sph (**6**).

With the desired glycosylsphingosines in hand, the conditions for efficient acylation to form target glycosphingolipids were explored. Similar to that reported previously,²³ palmitic acid in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and hydroxybenzotriazole (EDC-HCl/HOBt) led to successful acylation of the amino group in glycosylsphingosines but the reaction could not reach completion. In comparison, reactions of glycosylsphingosines with palmitoyl chloride in a mixed solvent of tetrahydrofuran (THF) and saturated NaHCO₃ solution (1:1, v/v) reached completion in 2 h. GM3 (**1**), GM2 (**12**), GM1 (**13**), fucosyl GM1 (**2**), GD3 (**3**), and GD2 (**4**) gangliosides were produced in 98–99% yields with facile C18 cartridge purification by eluting with 40–80% of CH₃CN in water (Table 1).

Table 1 Gangliosides formation by acylation of glycosylsphingosines.

Glycosylsphingosine	Ganglioside Product	C18 cartridge elution condition	Yield (%)
GM3 β Sph (6)	GM3 (1)	80% CH ₃ CN in H ₂ O	99
GM2 β Sph (7)	GM2 (12)	50% CH ₃ CN in H ₂ O	98
GM1 β Sph (8)	GM1 (13)	50% CH ₃ CN in H ₂ O	99
Fuc-GM1 β Sph (9)	Fucosyl GM1 (2)	50% CH ₃ CN in H ₂ O	99
GD3 β Sph (10)	GD3 (3)	50% CH ₃ CN in H ₂ O	99
GD2 β Sph (11)	GD2 (4)	40% CH ₃ CN in H ₂ O	98

Conclusions

In conclusions, combined with easy acylation and facile C18 cartridge purification schemes, sequential one-pot multienzyme (OPME) glycosylation systems are highly efficient in synthesizing a diverse array of gangliosides. As many bacterial glycosyltransferases are involved in the synthesis of glycolipid repeating units for the production of lipopolysaccharides and capsular polysaccharides, they can use glycosylsphingosines as acceptors for glycosylation although larger amounts of the enzymes may be needed in some cases. The production of gangliosides by sequential OPME glycosylation of water soluble lactosyl sphingosine with C18 cartridge purification followed by high-yield acylation is a highly efficient streamlined process. It is reasonable to assume that by incorporating various glycosyltransferases, the OPME systems can be applied to the synthesis of other challenging complex glycosphingolipids.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was supported by the National Institutes of Health (NIH) Common Fund Glycoscience Program grant U01GM120419. Bruker Avance-800 NMR spectrometer was funded by NSF grant DBIO-722538.

References

- K. Furukawa, Y. Ohmi, Y. Ohkawa, O. Tajima and K. Furukawa, *Adv. Neurobiol.*, 2014, **9**, 307-320.
- R. L. Schnaar, *J. Mol. Biol.*, 2016, **428**, 3325-3336.
- D. Lingwood and K. Simons, *Science*, 2010, **327**, 46-50.
- M. G. Jobling and R. K. Holmes, *Infect. Immun.*, 2002, **70**, 1260-1271.
- M. A. Martínez, S. López, C. F. Arias and P. Isa, *J. Virol.*, 2013, **87**, 1115-1122.
- R. W. Ledeen and G. Wu, *Trends Biochem. Sci.*, 2015, **40**, 407-418.
- I. Mocchetti, *Cell. Mol. Life Sci.*, 2005, **62**, 2283-2294.
- L. Svennerholm, *Life Sci.*, 1994, **55**, 2125-2134.
- J. Daniotti, A. Vilcaes, V. Torres Demichelis, F. Ruggiero and M. Rodríguez-Walker, *Front. Oncol.*, 2013, **3**, 306.
- M. A. Cheever, J. P. Allison, A. S. Ferris, O. J. Finn, B. M. Hastings, T. T. Hecht, I. Mellman, S. A. Prindiville, J. L. Viner, L. M. Weiner and L. M. Matrisian, *Clin. Cancer Res.*, 2009, **15**, 5323-5337.
- M. Kiso, H. Ishida, H. Ando and A. Imamura, in *Glycoscience: Biology and Medicine*, eds. N. Taniguchi, T. Endo, G. W. Hart, P. H. Seeberger and C.-H. Wong, Springer Japan, Tokyo, 2015, DOI: 10.1007/978-4-431-54841-6_31, pp. 331-338.
- Y. Liu, L. Wen, L. Li, M. R. Gadi, W. Guan, K. Huang, Z. Xiao, M. Wei, C. Ma, Q. Zhang, H. Yu, X. Chen, P. G. Wang and J. Fang, *Eur. J. Org. Chem.*, 2016, **2016**, 4315-4320.
- Y. Ito and J. C. Paulson, *J. Am. Chem. Soc.*, 1993, **115**, 1603-1605.
- R. I. Duclos, *Carbohydr. Res.*, 2000, **328**, 489-507.
- T. Murase, H. Ishida, M. Kiso and A. Hasegawa, *Carbohydr. Res.*, 1989, **188**, 71-80.
- Y. Matsuzaki, S. Nunomura, Y. Ito, M. Sugimoto, Y. Nakahara and T. Ogawa, *Carbohydr. Res.*, 1993, **242**, C1-6.
- H. Ishida, Y. Ohta, Y. Tsukada, M. Kiso and A. Hasegawa, *Carbohydr. Res.*, 1993, **246**, 75-88.
- J. R. Allen and S. J. Danishefsky, *J. Am. Chem. Soc.*, 1999, **121**, 10875-10882.
- T. K.-K. Mong, H.-K. Lee, S. G. Durón and C.-H. Wong, *Proc. Natl. Acad. Sci.*, 2003, **100**, 797-802.
- M. D. Vaughan, K. Johnson, S. DeFrees, X. Tang, R. A. Warren and S. G. Withers, *J. Am. Chem. Soc.*, 2006, **128**, 6300-6301.
- S.-I. Nishimura and K. Yamada, *J. Am. Chem. Soc.*, 1997, **119**, 10555-10556.
- S. Groux-Degroote, Y. Guerardel and P. Delannoy, *Chembiochem*, 2017, **18**, 1146-1154.
- A. Santra, Y. Li, H. Yu, T. J. Slack, P. G. Wang and X. Chen, *Chem. Commun.*, 2017, **53**, 8280-8283.
- X. L. Pan, T. Izumi, H. Yamada, K. Akiyoshi, S. Suenobu and S. Yokoyama, *Brain Develop.*, 2000, **22**, 196-198.
- T. N. Seyfried and P. Mukherjee, *J. Oncol.*, 2010, **2010**.
- H. Yu, H. Yu, R. Karpel and X. Chen, *Bioorg. Med. Chem.*, 2004, **12**, 6427-6435.
- V. Thon, Y. Li, H. Yu, K. Lau and X. Chen, *Appl. Microbiol. Biotechnol.*, 2012, **94**, 977-985.
- H. Yu, H. Chokhawala, R. Karpel, H. Yu, B. Wu, J. Zhang, Y. Zhang, Q. Jia and X. Chen, *J. Am. Chem. Soc.*, 2005, **127**, 17618-17619.
- G. Sugiarto, K. Lau, Y. Li, Z. Khedri, H. Yu, D. T. Le and X. Chen, *Mol. Biosyst.*, 2011, **7**, 3021-3027.
- G. Sugiarto, K. Lau, J. Qu, Y. Li, S. Lim, S. Mu, J. B. Ames, A. J. Fisher and X. Chen, *ACS Chem. Biol.*, 2012, **7**, 1232-1240.
- M. N. Dickler, G. Ragupathi, N. X. Liu, C. Musselli, D. J. Martino, V. A. Miller, M. G. Kris, F.-T. Brezicka, P. O. Livingston and S. C. Grant, *Clin. Cancer Res.*, 1999, **5**, 2773-2779.
- Q. S. C. Chu, B. Markman, N. Leighl, L. Krug, C. Rudin, D. Lathers, P. Basciano, P. M. Fracasso, G. Kollia, P. Phillips, G. Kolaitis, D. Williams, J. Jackson and N. Ready, *Ann. Oncol.*, 2016, **27**, 1427PD-1427PD.
- H. Yu, Y. Li, J. Zeng, V. Thon, D. M. Nguyen, T. Ly, H. Y. Kuang, A. Ngo and X. Chen, *J. Org. Chem.*, 2016, **81**, 10809-10824.
- Y. Li, H. Yu, Y. Chen, K. Lau, L. Cai, H. Cao, V. K. Tiwari, J. Qu, V. Thon, P. G. Wang and X. Chen, *Molecules*, 2011, **16**, 6396-6407.
- Y. Chen, V. Thon, Y. Li, H. Yu, L. Ding, K. Lau, J. Qu, L. Hie and X. Chen, *Chem. Commun.*, 2011, **47**, 10815-10817.
- K. Lau, V. Thon, H. Yu, L. Ding, Y. Chen, M. M. Muthana, D. Wong, R. Huang and X. Chen, *Chem. Commun.*, 2010, **46**, 6066-6068.
- X. Chen, J. Fang, J. Zhang, Z. Liu, J. Shao, P. Kowal, P. Andreana and P. G. Wang, *J. Am. Chem. Soc.*, 2001, **123**, 2081-2082.
- M. M. Muthana, J. Qu, Y. Li, L. Zhang, H. Yu, L. Ding, H. Malekan and X. Chen, *Chem. Commun.*, 2012, **48**, 2728-2730.
- H. Malekan, G. Fung, V. Thon, Z. Khedri, H. Yu, J. Qu, Y. Li, L. Ding, K. S. Lam and X. Chen, *Bioorg. Med. Chem.*, 2013, **21**, 4778-4785.
- C. Zhao, Y. Wu, H. Yu, I. M. Shah, Y. Li, J. Zeng, B. Liu, D. A. Mills and X. Chen, *Chem. Commun.*, 2016, **52**, 3899-3902.
- L. Engels and L. Elling, *Glycobiology*, 2014, **24**, 170-178.
- W. Yi, X. Liu, Y. Li, J. Li, C. Xia, G. Zhou, W. Zhang, W. Zhao, X. Chen and P. G. Wang, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**, 4207-4212.
- K. Hamamura, K. Furukawa, T. Hayashi, T. Hattori, J. Nakano, H. Nakashima, T. Okuda, H. Mizutani, H. Hattori, M. Ueda, T. Urano, K. O. Lloyd and K. Furukawa, *Proc. Natl. Acad. Sci. U. S. A.*, 2005, **102**, 11041-11046.
- A. S. Y. Lo, Q. Ma, D. L. Liu and R. P. Junghans, *Clin. Cancer Res.*, 2010, **16**, 2769-2780.
- V. Torres Demichelis, A. A. Vilcaes, R. Iglesias-Bartolomé, F. M. Ruggiero and J. L. Daniotti, *PLoS ONE*, 2013, **8**.
- J. Cheng, H. Yu, K. Lau, S. Huang, H. A. Chokhawala, Y. Li, V. K. Tiwari and X. Chen, *Glycobiology*, 2008, **18**, 686-697.
- M. Gilbert, J.-R. Brisson, M.-F. Karwaski, J. Michniewicz, A.-M. Cunningham, Y. Wu, N. M. Young and W. W. Wakarchuk, *J. Biol. Chem.*, 2000, **275**, 3896-3906.
- V. L. Battula, Y. Shi, K. W. Evans, R.-Y. Wang, E. L. Spaeth, R. O. Jacamo, R. Guerra, A. A. Sahin, F. C. Marini, G. Hortobagyi, S. A. Mani and M. Andreeff, *J. Clin. Invest.*, 2012, **122**, 2066-2078.
- S.-I. Hakomori, *Cancer Res.*, 1996, **56**, 5309-5318.
- B. H. Kushner, K. Kramer, S. Modak and N.-K. V. Cheung, *J. Clin. Oncol.*, 2011, **29**, 1168-1174.

Table of Contents

Highly efficient streamlined total synthesis of complex prioritized gangliosides was achieved chemoenzymatically by sequential one-pot multienzyme (OPME) reactions with facile C18 cartridge purification schemes followed by high-yield acylation.

